Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2,4-diaminopteridin-6-yl)-methyl-dibenz[b,f]azepine is an experimental small molecule inhibitor designed as a selective antifolate. It acts by inhibiting dihydrofolate reductase (DHFR), with high selectivity for the DHFR enzymes of Pneumocystis carinii and Toxoplasma gondii over mammalian DHFR. This selectivity is attributed to its bulky dibenzoazepine moiety fitting into unique regions of the microbial enzyme active sites not present in mammalian counterparts. The compound has been studied as a potential lead for developing antiparasitic agents targeting opportunistic infections in immunocompromised patients[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2,4-diaminopteridin-6-yl)-methyl-dibenz[b,f]azepine.